Where does Accutar Biotechnology Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Accutar Biotechnology Inc. ranks #14,422 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Accutar Biotechnology Inc. hold?

Accutar Biotechnology Inc. holds 20 US utility patents granted between 2018 and 2025, spanning 8 technology areas.

What is Accutar Biotechnology Inc.'s Innovation Score?

Accutar Biotechnology Inc. has an Innovation Score of 41.1 out of 100 (top 34% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Accutar Biotechnology Inc. focus on?

Accutar Biotechnology Inc.'s top technology area is C07D (Heterocyclic Compounds) with 17 patents, ranking #514 of 3,165 assignees active in that subclass. Grants appear in 8 CPC subclasses total.

Is Accutar Biotechnology Inc.'s patent grant rate increasing or decreasing?

Accutar Biotechnology Inc.'s recent grant velocity is +400% compared to the prior five-year period (grant years, not application filing dates). This indicates accelerating grant output.

What does claim depth mean for Accutar Biotechnology Inc.'s patents?

Accutar Biotechnology Inc.'s patents average 24.5 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Accutar Biotechnology Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Accutar Biotechnology Inc.

USPTO PatentsView assignee record - 20 granted patents across 8 technology areas, recorded in grant years 2018–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07D (Heterocyclic Compounds).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Accutar ranks #14,422 of 49,997 tracked US assignees by granted-patent volume, with 20 patents across 8 technology areas.

#14,422
of 49,997 US assignees by volume: Top 34%
by Innovation Score (41.1/100): 24.5
avg claims per patent: +400%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R14422 · US Corporation #14,422 · 20 grants

GRANTS-SMALL · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-DENSE · TYPE-USCORP · VEL-SURGE · BOOK-FULL

GRANTS-SMALL 20 grants
MID-PACK #14,422/49,997
PHOTO-FINISH Aalto University
CPC-NARROW C07D · 8 areas
INNOV-PAR 41.1/100
CLAIMS-DENSE 24.5 claims/avg
TYPE-USCORP US Corporation
VEL-SURGE +400% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Aalto University (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Accutar’s 41.1 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 10.5 pts (26%) Velocity 5.9 pts (14%) Breadth 10.0 pts (24%) Claim depth 14.7 pts (36%)

Qualcomm Incorporated · highest

85
Accutar Biotechnology · this assignee

41
3D Lighting… · lowest

7

What this shows Accutar's Innovation Score is 41.1/100 (top 34% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Accutar?

Each dot is one of Accutar’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Accutar’s own 24.5 claims/patent is ABOVE the 15.8 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Accutar vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Accutar's grants concentrate

Accutar Biotechnology Inc. is a focused PatentsView assignee: 8 CPC subclasses with 85% of grants classified under C07D (Heterocyclic Compounds). Peak complete grant year is 2022 (7 grants) versus a trough of 1 in 2018. By volume, Accutar sits between Aalto University and Additive Technologies LLC.

Accutar's three-year grant acceleration

Accutar Biotechnology Inc. shows 8 grants in 2022–2024 against only 9 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Aalto University

20
Abbott Laboratori…

20
Abyrx

20
Accelerate Diagno…

20
Aclaris Therapeut…

20
Actimize

20
Actionpower

20
Additive

20
Accutar Biotechno… ◀

20

What this shows Accutar holds 20 patents at rank #14,447, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Accutar

By rank, the assignees closest to #14,447 in granted patent volume.

Leaders in C07D (Heterocyclic Compounds)

Other assignees with the most granted patents in Accutar's primary technology class.

Accutar's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

41 Top 34% higher than 66% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2018–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2018–2019 baseline. Full figures in the table below.

View data table

Accutar Biotechnology Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2018	1	5.0%
2019	2	10.0%
2020	4	20.0%
2021	3	15.0%
2022	7	35.0%
2023	1	5.0%
2025partial year	2	10.0%

Which technologies does Accutar Biotechnology Inc. patent most?

C07D - Heterocyclic Compounds 17

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 13

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 6

C07K - Peptides 3

G06N - Computing Arrangements Based ON Specific Computational Models 2

G16C - Computational CHEMISTRY; CHEMOINFORMATICS; Computational Materials Science 2

G16B - Bioinformatics, i.e. Information AND Communication Technology [ICT] Specially Adapted FOR Genetic OR Protein-related Data Processing IN Computational Molecular Biology 1

Y02A - Technologies FOR Adaptation TO Climate Change 1

Top 8 of 8 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Accutar Biotechnology Inc.'s patent record in context - here's where to go next.

Accutar Biotechnology Inc.'s lead technology class is C07D (Heterocyclic Compounds), 85% of its portfolio - see every assignee active in that class. Explore C07D
Ranked #14,422 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Accutar Biotechnology Inc. against Aalto University, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 41.1/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.